Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids.

[1]  K. Jóźwiak,et al.  Effects of Linkers and Substitutions on Multitarget Directed Ligands for Alzheimer’s Diseases: Emerging Paradigms and Strategies , 2022, International journal of molecular sciences.

[2]  F. García-Carmona,et al.  The use of cyclodextrins as solubility enhancers in the ORAC method may cause interference in the measurement of antioxidant activity. , 2022, Talanta.

[3]  Wenyuan Liu,et al.  Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection. , 2021, Journal of medicinal chemistry.

[4]  T. Horvath,et al.  Therapy for Alzheimer’s disease: Missing targets and functional markers? , 2021, Ageing Research Reviews.

[5]  Razi Ahmad,et al.  Alzheimer's disease and its treatment by different approaches: A review. , 2021, European journal of medicinal chemistry.

[6]  Rikang Wang,et al.  Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease. , 2021, European journal of medicinal chemistry.

[7]  F. Seixas,et al.  Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation. , 2021, Bioorganic & medicinal chemistry.

[8]  Zhenyuan Miao,et al.  Design, synthesis and biological evaluation of novel 31-hexyloxy chlorin e6-based 152- or 131-amino acid derivatives as potent photosensitizers for photodynamic therapy. , 2020, European journal of medicinal chemistry.

[9]  P. Crooks,et al.  Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation , 2020, Molecules.

[10]  M. Yar,et al.  Free radical scavengers: An overview on heterocyclic advances and medicinal prospects. , 2020, European journal of medicinal chemistry.

[11]  Weizhong Tang,et al.  Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease. , 2020, European journal of medicinal chemistry.

[12]  A. Srivastava,et al.  Near-Infrared Responsive Dopamine/Melatonin-Derived Nanocomposites Abrogating in Situ Amyloid β Nucleation, Propagation, and Ameliorate Neuronal Functions. , 2020, ACS applied materials & interfaces.

[13]  Wenjian Tang,et al.  Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies. , 2019, European journal of medicinal chemistry.

[14]  M. Scheiner,et al.  Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model. , 2019, Journal of Medicinal Chemistry.

[15]  Hua Zhang,et al.  Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation , 2019, Molecules.

[16]  Ki Duk Park,et al.  Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator. , 2019, ACS medicinal chemistry letters.

[17]  Q. Guo,et al.  Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation. , 2019, Bioorganic chemistry.

[18]  V. Lather,et al.  Aegle marmelos leaf extract ameliorates the cognitive impairment and oxidative stress induced by intracerebroventricular streptozotocin in male rats , 2019, Life sciences.

[19]  Dongwei Kang,et al.  Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. , 2019, Drug discovery today.

[20]  N. Beriwal,et al.  Role of immune-pineal axis in neurodegenerative diseases, unraveling novel hybrid dark hormone therapies , 2019, Heliyon.

[21]  Yi Jin,et al.  Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation. , 2018, Bioorganic chemistry.

[22]  Xiaobing Wang,et al.  Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties. , 2018, European journal of medicinal chemistry.

[23]  W. Fu,et al.  Drug candidates in clinical trials for Alzheimer’s disease , 2017, Journal of Biomedical Science.

[24]  C. Pérez,et al.  New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. , 2016, European journal of medicinal chemistry.

[25]  G. Logroscino,et al.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease , 2016, BioMed research international.

[26]  A. Chatonnet,et al.  Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse , 2016, Behavioural Brain Research.

[27]  S. Chiou,et al.  Molecular docking of different inhibitors and activators to butyrylcholinesterase , 2015, Journal of biomolecular structure & dynamics.

[28]  Yan Li,et al.  Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease. , 2015, Bioorganic & Medicinal Chemistry.

[29]  J. Hayes,et al.  The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. , 2014, Trends in biochemical sciences.

[30]  C. Sotriffer,et al.  Structure-Based Search for New Inhibitors of Cholinesterases , 2013, International journal of molecular sciences.

[31]  M. Suckow,et al.  Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier. , 2012, ACS chemical neuroscience.

[32]  A. Contestabile.  The history of the cholinergic hypothesis , 2011, Behavioural Brain Research.

[33]  Masayuki Yamamoto,et al.  Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[34]  G. Perry,et al.  Oxidative stress in Alzheimer disease: A possibility for prevention , 2010, Neuropharmacology.

[35]  D. Praticò.  Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. , 2008, Trends in pharmacological sciences.

[36]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[37]  Shyam Biswal,et al.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.

[38]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[39]  M. Tuzcu,et al.  Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats , 2005, Brain Research.

[40]  B. P. Doctor,et al.  Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. , 1999, Chemico-biological interactions.

[41]  J. Muir,et al.  Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease , 1997, Behavioural Brain Research.

[42]  M. Emmerling.  Human Cholinesterases and Anticholinesterases by Hermona Soreq and Haim Zakut, Academic Press, 1993. $84.95 (xiv + 314 pages) ISBN 0 12 655290 8 , 1994, Trends in Neurosciences.

[43]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[44]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[45]  G. Elder,et al.  Transgenic mouse models of Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.